1801.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 10:08):

Stats
Tagesvolumen	7.41M
Durchschnittsvolumen	9.31M
Marktkapitalisierung	66.37B
EPS	HKD0 ( 2024-03-25 )
Nächstes Ertragsdatum	( HKD0 ) 2024-06-20
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-57.61
ATR14	HKD0.0430 (0.11%)

Volumen Korrelation

Lang: -0.19 (neutral)

Kurz: 0.18 (neutral)

Signal:(51.595) Neutral

Innovent Biologics Inc Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Innovent Biologics Inc Korrelation - Währung/Rohstoff

0.29
( neutral )

0.10
( neutral )

0.00
( neutral )

0.12
( neutral )

-0.61
( weak negative )

-0.12
( neutral )

Innovent Biologics Inc Finanzdaten

Annual	2023
Umsatz:	HKD6.21B
Bruttogewinn:	HKD5.07B (81.69 %)
EPS:	HKD-0.660

FY	2023
Umsatz:	HKD6.21B
Bruttogewinn:	HKD5.07B (81.69 %)
EPS:	HKD-0.660

FY	2022
Umsatz:	HKD4.56B
Bruttogewinn:	HKD3.63B (79.57 %)
EPS:	HKD-1.460

FY	2021
Umsatz:	HKD4.27B
Bruttogewinn:	HKD3.70B (86.58 %)
EPS:	HKD-2.31

Financial Reports:

No articles found.

Innovent Biologics Inc

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.